Oculis Holding Ag · NASDAQ:OCS
Oculis — Corporate Update (October 2025)
15 slides from Oculis's corporate update, Oct 6, 2025
Slide 1: Rethinking Ophthalmology: Privosegtor FDA update
Rethinking Ophthalmology Privosegtor FDA update October 6th, 2025 Exhibit 99.2
Slide 2: Forward-looking statements
These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre
Slide 3: Corporate Update
Corporate Update
Slide 4: Three registrational programs in Neuro-Ophthalmic and Retina indications provide multi-billion-dollar market opportunities
Three registrational programs in Neuro-Ophthalmic and Retina indications provide multi-billion-dollar market opportunities Oculis (Nasdaq / XICE: OCS) Global biopharma Nasdaq listed company Innovative neuro-ophthalmology and ophthalmology candidates with significant market potential of ~$25 billion
Slide 5: Allows advancement of Privosegtor into the registrational phase
Allows advancement of Privosegtor into the registrational phase Alignment on the acute optic neuritis (AON) registrational trial design Alignment on the regulatory pathway for non-arteritic anterior ischemic optic neuropathy (NAION), to be evaluated under the same IND AON: PIONEER-1 registrational t
Slide 6: Privosegtor Development Plan
Pre-clinical Phase 1 Phase 2 Phase 3 Next catalysts Start of PIONEER-1 registrational trial in Q4 2025 Start of PIONEER-2 registrational trial in 1H 2026 Start of PIONEER-3 registrational trial in mid-2026 Oculis to cross-reference Privosegtor AON IND for new IND submission in MS Relapses in 2026 AO
Slide 7: PIONEER-1 and PIONEER-2 Registration Trials in Acute Optic Neuritis
Dose and population mirrors successful Phase 2 ACUITY trial PIONEER-1 and PIONEER-2 Registration Trials in Acute Optic Neuritis Screening 5-day treatment 6-month evaluation period Privosegtor + steroid (n=70-80) Placebo + steroid (n=70-80) Month 6 Primary Evaluation Results Day 5 Month 1 Month 3 Pri
Slide 8: The PIONEER Program: Oculis' Neuro-Ophthalmology Strategy
AON: Similar design to ACUITY NAION: Registrational Plan Broad indications 1 2 Registrational trials evaluating AON and NAION to support registration plans in both indications The PIONEER Program: Oculis’ Neuro-Ophthalmology Strategy AON: PIONEER-1 & PIONEER-2 All comers similar to ACUITY trial: MS
Slide 9: Acute Optic Neuritis: orphan indication with >30K patients a year (US)
Orphan indication with >30K patients a year (US)1,2 Acute inflammation of the optic nerve impacting Optic nerve & retinal ganglion cells Acute Optic Neuritis An acute inflammation of the optic nerve that can lead to permanent visual impairment in young adults with an average age of 32 years Inflamma
Slide 10: Privosegtor could be the first neuroprotective therapy: Acute Optic Neuritis U.S. Potential Market
Privosegtor could be the first neuroprotective therapy to improve vision outcomes Acute Optic Neuritis – U.S. Potential Market High unmet need in rare disease with large market potential Weidong Gu et al. (2023) Incidence of Optic Neuritis and the Associated Risk of Multiple Sclerosis for Service Me
Slide 11: Non-arteritic Anterior Ischemic Optic Neuropathy: no treatment approved
No treatment approved, with severe vision loss in > 60% patients Non-arteritic Anterior Ischemic Optic Neuropathy Orphan indication with US incidence of >30K1 RGC, axons and optic nerve atrophy caused by hypoperfusion3 leading to vision loss Non-arteritic anterior ischemic optic neuropathy (NAION) r
Slide 12: Privosegtor could be the first neuroprotective therapy: NAION U.S. Potential Market
Privosegtor could be the first neuroprotective therapy to improve vision outcomes NAION – U.S. Potential Market Significant opportunity for novel therapy to improve the current poor prognosis in NAION Incidence of nonarteritic anterior ischemic optic neuropathy – PubMed and Incidence of nonarteritic
Slide 13: Multiple Pivotal Milestones Focusing on Significant Unmet Medical Needs
Pre-clinical Phase 1 Phase 2 Phase 3 Next catalysts Start of PIONEER-1 registrational trial in Q4 2025 Start of PIONEER-2 registrational trial in 1H 2026 Start of PIONEER-3 registrational trial in mid-2026 Oculis to cross-reference Privosegtor AON IND for new IND submission in MS Relapses in 2026 DI
Slide 14: Oculis Pipeline Development Strategic Evolution
Oculis Pipeline Development Strategic Evolution ~$10B1,2 Advance OCS-01 would be the first-ever topical treatment in DME, if approved Licaminlimab as personalized medicine in DED Privosegtor neuroprotection in Acute Optic Neuritis +$25B1-3 Expand Privosegtor in Neuro-ophthalmology and beyond NAION M
Slide 15: H hinki
4 = f e “= vi H hinki Oc u | | S | Sorta